Trial · NCT01583374
Participant flow108
How many started, completed or left each group, period by period.
1 to 20 of 108
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Placebo-controlled Phase (Week 0-24) | STARTED | Placebo | 164 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 20 mg | 163 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 30 mg | 163 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Placebo / Apremilast 30 mg Early Escape (EE) | 0 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Placebo/Apremilast 30 mg Crossover (XO) | 0 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 30 mg /Apremilast 30 mg EE | 0 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 20 mg /Apremilast 30 mg EE | 0 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 30 mg /Apremilast 30 mg Second Escape (SE) | 0 | |
| Placebo-controlled Phase (Week 0-24) | STARTED | Apremilast 20 mg/Apremilast 30 mg SE | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Placebo | 164 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 20 mg | 163 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 30 mg | 163 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Placebo / Apremilast 30 mg Early Escape (EE) | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Placebo/Apremilast 30 mg Crossover (XO) | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 30 mg /Apremilast 30 mg EE | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 20 mg /Apremilast 30 mg EE | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 30 mg /Apremilast 30 mg Second Escape (SE) | 0 | |
| Placebo-controlled Phase (Week 0-24) | Received Treatment | Apremilast 20 mg/Apremilast 30 mg SE | 0 | |
| Placebo-controlled Phase (Week 0-24) | Completed Week 16 | Placebo | 150 | |
| Placebo-controlled Phase (Week 0-24) | Completed Week 16 | Apremilast 20 mg | 151 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01583374/flow